Why MSI-high cancers are more responsive to immune checkpoint inhibitors Annual Meeting GI 2016

Why MSI-high cancers are more responsive to immune checkpoint inhibitors Annual Meeting GI 2016

1,122 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses why MSI-high cancers are more responsive to immune checkpoint inhibitors at ASCO GI 2016
Up Next Autoplay